New chemo cocktail aims to stop colon Cancer's return

NCT ID NCT05179889

Recruiting now Disease control Sponsor: Chungnam National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial compares two chemotherapy combinations after surgery for people with high-risk stage III colon cancer. About 308 participants will receive either mFOLFIRINOX or the standard mFOLFOX6 for 12 cycles. The goal is to see if the stronger combo delays cancer recurrence and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (irinotecan, oxaliplatin, leucovorin, 5-FU)
What this could lead to: If successful, this could show that a stronger chemo combo (mFOLFIRINOX) helps prevent colon cancer from coming back after surgery better than the current standard.
What could go wrong: This is a mid-stage trial, so results are not yet proven. The stronger chemo may cause more side effects, and it may not improve survival or recurrence rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colonic neoplasm malignant colon neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER STAGE III

Contacts and locations

Locations

Chungnam National University Hospital
RECRUITING

Daejeon, 34112, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.